Business
Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics
Financing led by The Venture Collective with participation from Merck Global Health Innovation Fund, Artis Ventures, First Spark Ventures, argenx, Droia Ventures and existing investorsSANTA CRUZ, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Unnatural Products, a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced the closing of a $45 million Series B financing led by The Venture Collective (TVC), with participation from argenx, Droia
About this update from Argenx Se
[{"type":"image","alt":"Unnatural Products Inc.","displaySize":"","headline":null,"caption":"Unnatural Products Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":131,"url":"https://media.zenfs.com/en/globenewswire.com/5ad52af3e12a8597b98f6da9024f1805"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hS0CILuSS3AKeS1MbRYknw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5ad52af3e12a8597b98f6da9024f1805","width":300,"height":131}},"lazy":false},{"type":"text","content":"Financing led by The Venture Collective with participation from Merck Global Health Innovation Fund, Artis Ventures, First Spark Ventures, argenx, Droia Ventures and existing investors","length":184,"tagName":"p"},{"type":"text","content":"SANTA CRUZ, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Unnatural Products, a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced the closing of a $45 million Series B financing led by The Venture Collective (TVC), with participation from argenx, Droia Ventures and existing investors Merck Global Health Innovation Fund, Artis Ventures, and First Spark Ventures.","length":426,"tagName":"p"},{"type":"text","content":"The funding will support development of the company’s proprietary drug discovery platform and advance its pipeline of macrocyclic peptide therapeutics designed to address historically difficult-to-drug or “undruggable” targets.","length":227,"tagName":"p"},{"type":"text","content":"Last month, Unnatural Products announced a licensing agreement with Novartis to develop macrocyclic peptide therapeutics for historically undruggable cardiovascular targets, including up to $100 million upfront and up to $1.7 billion in total potential milestones.","length":264,"tagName":"p"},{"type":"text","content":"“Macrocyclic peptides represent a powerful new therapeutic modality,” said Cameron Pye, Chief Executive Officer and Co-Founder, Unnatural Products. “Our platform unlocks the precision of biologics with the delivery advantages of small molecules, enabling us to target complex intracellular pathways that have historically been out of reach. We can also provide oral solutions to targets only currently addressable with costly injectables. This financing allows us to accelerate development of our pipeline a...